RDHL Redhill Biopharma Ltd.

6.05
-0.11  -2%
Previous Close 6.16
Open 6.39
Price To Book 3.56
Market Cap 213,380,874
Shares 35,269,566
Volume 383,078
Short Ratio
Av. Daily Volume 286,558
Stock charts supplied by TradingView

NewsSee all news

  1. RedHill Biopharma Completes Acquisition of Movantik® from AstraZeneca

    RedHill to promote Movantik® in the U.S. to expanded call points, including gastroenterologists, primary care physicians and additional specialists, along with Talicia® and Aemcolo® Movantik® generated U.S. net sales of

  2. RedHill Biopharma to Present at Upcoming Investor Conferences in September

    TEL-AVIV, Israel and RALEIGH, N.C., Aug. 27, 2019 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (NASDAQ:RDHL) (Tel-Aviv Stock Exchange: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company primarily

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Phase 3 trial to be initiated 3Q 2020.
RHB-204
Nontuberculous mycobacteria (NTM) infections
Phase 2a enrolment of second arm has been initiated - March 11, 2020.
YELIVA
Cholangiocarcinoma
Phase 3 data released July 30, 2018. Primary endpoint met but further trial required.
RHB-104 MAP
Crohn’s disease
FDA Approval announced November 4, 2019.
Talicia RHB-105
H. pylori
Phase 3 additional trial planned.
BEKINDA
Gastroenteritis
Phase 2 top-line data released October 3, 2017 - primary endpoint met (borderline) - p=0.05. Follow up analysis identfied p value = 0.036. Phase 3 trial planned.
BEKINDA
IBS-D

Latest News

  1. RedHill Biopharma Completes Acquisition of Movantik® from AstraZeneca

    RedHill to promote Movantik® in the U.S. to expanded call points, including gastroenterologists, primary care physicians and additional specialists, along with Talicia® and Aemcolo® Movantik® generated U.S. net sales of

  2. RedHill Biopharma to Present at Upcoming Investor Conferences in September

    TEL-AVIV, Israel and RALEIGH, N.C., Aug. 27, 2019 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (NASDAQ:RDHL) (Tel-Aviv Stock Exchange: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company primarily